Astragaloside improves outcomes of traumatic brain injury in rats by reducing microglia activation

Am J Chin Med. 2014;42(6):1357-70. doi: 10.1142/S0192415X14500852.

Abstract

Astragaloside (AST) is traditionally prescribed for the prevention and treatment of cerebrovascular diseases. We directly tested the therapeutic effects of AST in a rat model of traumatic brain injury (TBI). One hour after the onset of TBI rats were given Saline (1 ml/kg) or AST (20-80 mg/kg) via i.p. injection. AST causes the attenuation of TBI-induced cerebral contusion, neuronal apoptosis, and neurological motor dysfunction. TBI-induced microglial activation evidenced by the morphological transformation of microglia (or ameboid microglia) and the microglial overexpression of tumor necrosis factor-alpha was reduced by AST. Our results indicate that AST may protect against brain contusion and neuronal apoptosis after TBI by attenuating microglia activation in male rats.

Keywords: Astragaloside; Microglia; Traumatic Brain Injury; Tumor Necrosis Factor-Alpha.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Brain / cytology*
  • Brain / pathology*
  • Brain Injuries / drug therapy*
  • Brain Injuries / metabolism
  • Brain Injuries / pathology*
  • Disease Models, Animal
  • Drugs, Chinese Herbal / administration & dosage*
  • Drugs, Chinese Herbal / pharmacology
  • Injections, Intraperitoneal
  • Male
  • Microglia / metabolism
  • Microglia / pathology*
  • Motor Activity / drug effects
  • Phytotherapy*
  • Rats, Sprague-Dawley
  • Saponins / administration & dosage*
  • Saponins / pharmacology
  • Triterpenes / administration & dosage*
  • Triterpenes / pharmacology
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Drugs, Chinese Herbal
  • Saponins
  • Triterpenes
  • Tumor Necrosis Factor-alpha
  • astragaloside A